Literature DB >> 22641135

Rheumatoid arthritis: Evidence-based rather than habit-based treatment options.

Yusuf Yazici.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22641135     DOI： 10.1038/nrrheum.2012.79

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

1.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Authors:  T Möttönen; P Hannonen; M Leirisalo-Repo; M Nissilä; H Kautiainen; M Korpela; L Laasonen; H Julkunen; R Luukkainen; K Vuori; L Paimela; H Blåfield; M Hakala; K Ilva; U Yli-Kerttula; K Puolakka; P Järvinen; M Hakola; H Piirainen; J Ahonen; I Pälvimäki; S Forsberg; K Koota; C Friman
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

2.  Treatment of rheumatoid arthritis: we are getting there.

Authors:  Yusuf Yazici
Journal:  Lancet       Date:  2009-06-26       Impact factor: 79.321

3.  Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.

Authors:  M A Cimmino; G Leardini; F Salaffi; M Intorcia; A Bellatreccia; D Dupont; A Beresniak
Journal:  Clin Exp Rheumatol       Date:  2011-08-31       Impact factor: 4.473

Review 4.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

5.  Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.

Authors:  Yvonne P M Goekoop-Ruiterman; Jeska K de Vries-Bouwstra; Cornelia F Allaart; Derkjen van Zeben; Pit J S M Kerstens; J Mieke W Hazes; Aelko H Zwinderman; André J Peeters; Johanna M de Jonge-Bok; Constant Mallée; Wim M de Beus; Peter B J de Sonnaville; Jacques A P M Ewals; Ferdinand C Breedveld; Ben A C Dijkmans
Journal:  Ann Intern Med       Date:  2007-03-20       Impact factor: 25.391

6.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

7.  Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis.

Authors:  Y Yazici; H Yazici
Journal:  Clin Exp Rheumatol       Date:  2008 May-Jun       Impact factor: 4.473

8.  Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis.

Authors:  Yusuf Yazici; Svetlana Krasnokutsky; Jaime P Barnes; Patricia L Hines; Jason Wang; Lisa Rosenblatt
Journal:  J Rheumatol       Date:  2009-03-30       Impact factor: 4.666

9.  Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.

Authors:  Moetaza M Soliman; Kimme L Hyrich; Mark Lunt; Kath D Watson; Deborah P M Symmons; Darren M Ashcroft
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-08       Impact factor: 4.794
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.